department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

AMGEN INC ($AMGN) · pipeline · pharmadog

← back to AMGEN INC

Pipeline · $AMGN

33 products

MarketedAMJEVITAAMJEVITA (ADALIMUMAB-ATTO)MarketedCorlanorCorlanor (ivabradine hydrochloride)Congestive Heart Failure (Heart Failure)MarketedWEZLANAWEZLANA (USTEKINUMAB-AUUB)MarketedXgevaXgeva (denosumab)Bone Metastasis Marketedapremilast EROtezla XR (apremilast)Behcet Disease MarketedblinatumomabBlincyto (blinatumomab)B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)MarketedcarfilzomibKyprolis (carfilzomib)Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)Marketeddarbepoetin alfa LAAranesp (darbepoetin alfa)Anemia in Chronic Kidney Disease (Renal Anemia)MarketeddenosumabProlia (denosumab)Glucocorticoid-Induced Osteoporosis Marketedeculizumab biosimilarBkemv (ECULIZUMAB-AEEB)Paroxysmal Nocturnal Hemoglobinuria Marketedepoetin alfaEpogen (epoetin alfa)Chemotherapy Induced Anemia MarketederenumabAimovig (erenumab-aooe)Migraine MarketedetanerceptEnbrel (etanercept)Plaque Psoriasis (Psoriasis Vulgaris)Marketedetelcalcetide hydrochlorideParsabiv (etelcalcetide hydrochloride)Secondary Hyperparathyroidism MarketedevolocumabRepatha (evolocumab)Atherosclerosis MarketedpanitumumabVectibix (panitumumab)Metastatic Colorectal Cancer MarketedsotorasibLumakras (sotorasib)Metastatic Colorectal Cancer Marketedtalimogene laherparepvecImlygic (talimogene laherparepvec)Metastatic Melanoma MarketedtarlatamabImdelltra (tarlatamab-dlle)Small-Cell Lung Cancer MarketedtezepelumabTezspire (tezepelumab-ekko)Eosinophilic Esophagitis Phase 3olpasiranAtherosclerosis Phase 3romiplostimNplate (romiplostim)Thrombocytopenia Phase 3romosozumabEvenity (romosozumab-aqqg)Osteogenesis Imperfecta Phase 3xaluritamigxaluritamig [INN]Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2anvumetostatanvumetostat [INN]Metastatic Biliary Tract Cancer Phase 1AMG-513Obesity PreclinicalHalf-Life Extended BiTEAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)AVSOLAAVSOLA (INFLIXIMAB-AXXQ)BKEMVBKEMV (ECULIZUMAB-AEEB)1 INDICATIONS AND USAGE BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) 1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) BKEMV is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (aHUS) BKEMV is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). 1.3 Generalized Myasthenia Gravis (gMG) BKEMV is indicated for treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.BLINCYTOBLINCYTO (BLINATUMOMAB)1 INDICATIONS AND USAGE BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 ) 1.1 MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older. 1.2 Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older. 1.3 B-cell Precursor ALL in the Consolidation Phase BLINCYTO is indicated for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older.

← prevpage 1 of 2next →